|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||142.67 - 146.87|
|52 Week Range||96.14 - 147.91|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||41.27|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||161.20|
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Masimo Corp NASDAQ/NGS:MASIView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MASI with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MASI. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MASI totaled $161 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Masimo announced today that O3® Regional Oximetry has received FDA clearance for use on neonatal and infant patients . O3 may help clinicians monitor cerebral oxygenation in situations in which peripheral pulse oximetry alone may not be fully indicative of the oxygen in the brain.
How do we determine whether Masimo Corporation (NASDAQ:MASI) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
NextGen (NXGN) Q4 results benefit from better performing recurring segment. However, gross margin contraction remains a woe.
NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.
NuVision to Deploy Masimo SET®, Root® with Radical-7®, NomoLine® Capnography, and Patient SafetyNet™ at Four Locations
Results of the study of ExcelsiusGPS reached a milestone for Globus Medical (GMED) in the field of robotics-assisted, minimally invasive pedicle screw placement procedure
Excluding the Diabetes group, Medtronic (MDT) displays better performances at CER on the back of growth in rest of the business segments and across all geographies.
Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.
Within Neurovascular, we hope to witness strength across Medtronic's (MDT) stroke franchise with growth in stent retrievers, flow diverters, neuro access and embolic products.
Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.